Xenon Pharmaceuticals (NASDAQ:XENE) CEO Purchases $1,121,400.00 in Stock

04 Oct 2026, 09:26 by Mitch Edgeman · The Markets Daily

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) CEO Ian Mortimer purchased 30,000 shares of the stock in a transaction dated Wednesday, September 30th. The shares were acquired at an average price of $37.38 per share, for a total transaction of $1,121,400.00. Following the acquisition, the chief executive officer directly owned 49,923 shares of the company’s stock, valued at $1,866,121.74. This represents a 150.58% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Xenon Pharmaceuticals Trading Down 2.3%

Shares of Xenon Pharmaceuticals stock opened at $38.02 on Friday. Xenon Pharmaceuticals Inc. has a 1 year low of $36.07 and a 1 year high of $72.66. The company has a market cap of $3.68 billion, a P/E ratio of -8.02 and a beta of 0.60. The stock has a 50-day moving average price of $56.32 and a 200 day moving average price of $57.02.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same period in the previous year, the firm posted ($1.07) EPS. On average, equities analysts forecast that Xenon Pharmaceuticals Inc. will post -4.7 earnings per share for the current fiscal year.

Key Xenon Pharmaceuticals News

Here are the key news stories impacting Xenon Pharmaceuticals this week:

Positive Sentiment: CEO Ian Mortimer purchased 30,000 shares for approximately $1.12 million, while CFO Thomas Patrick Kelly bought 15,000 shares for about $559,800. The combined purchases, made near $37 per share, may reassure investors that senior management views the recent weakness as an attractive entry point. Insider Buying: Xenon Pharmaceuticals CFO Buys $559,800 in Stock
Positive Sentiment: RBC said safety issues are unlikely to derail the approval path for azetukalner (XEN1101), Xenon’s lead investigational treatment for epilepsy and major depressive disorder. This reduces concern that safety questions could materially delay a key development catalyst. Xenon’s AZK Approval Path Unlikely to Be Hurt by Safety Issues
Neutral Sentiment: Xenon granted eight newly hired, non-officer employees 17,850 stock options and 10,500 restricted share units under Nasdaq’s inducement-grant exemption. The awards support recruitment but could modestly increase future share dilution. Xenon Pharmaceuticals Reports Inducement Grants
Negative Sentiment: Although analysts maintain a broadly positive consensus, recent target-price reductions—including Deutsche Bank’s cut to $46 from $90—highlight continuing concerns about valuation, execution and the path to commercialization. Xenon remains loss-making, with analysts expecting a full-year loss of approximately $4.70 per share.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. increased its position in Xenon Pharmaceuticals by 450.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 900 shares during the last quarter. Global Retirement Partners LLC bought a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter worth about $53,000. Clearstead Advisors LLC boosted its stake in shares of Xenon Pharmaceuticals by 214.8% during the 4th quarter. Clearstead Advisors LLC now owns 1,215 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 829 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at about $55,000. Finally, Quantbot Technologies LP acquired a new position in shares of Xenon Pharmaceuticals during the 2nd quarter valued at about $57,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Wall Street Analyst Weigh In

XENE has been the topic of a number of research reports. Wall Street Zen raised shares of Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday. Wells Fargo & Company lowered their target price on Xenon Pharmaceuticals from $69.00 to $64.00 and set an “overweight” rating on the stock in a research note on Friday, September 18th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $90.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, September 28th. Robert W. Baird cut their price target on Xenon Pharmaceuticals from $97.00 to $90.00 and set an “outperform” rating for the company in a research note on Friday, September 18th. Finally, Wedbush reduced their price target on Xenon Pharmaceuticals from $71.00 to $55.00 and set an “outperform” rating for the company in a report on Friday, September 18th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $70.27.

Get Our Latest Research Report on XENE

Xenon Pharmaceuticals Company Profile

(Get Free Report)

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses research in ion channels and neuronal signaling to identify potential treatments for conditions with significant unmet medical needs.